Kymera Therapeutics

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the